Difference between revisions of "Pictilisib (GDC-0941)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=641462 NCI Drug Dictionary]: The orally bioavailable bismesylate salt of a po...") |
m |
||
| Line 7: | Line 7: | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
| − | [[Category: | + | [[Category:PI3K inhibitors]] |
[[Category:Investigational]] | [[Category:Investigational]] | ||
Revision as of 01:16, 1 January 2016
Mechanism of action
From the NCI Drug Dictionary: The orally bioavailable bismesylate salt of a potent small-molecule thieno[3,2-d]pyrimidine inhibitor of the class I phosphatidylinositol 3 kinase (PI3K) isoforms p100alpha and p100delta with potential antineoplastic activity. PI3K inhibitor GDC-0941 selectively binds to PI3K isoforms in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway.